دورية أكاديمية
Chlorhexidine and Mupirocin for Clearance of Methicillin-Resistant Staphylococcus aureus Colonization After Hospital Discharge: A Secondary Analysis of the Changing Lives by Eradicating Antibiotic Resistance Trial.
| العنوان: | Chlorhexidine and Mupirocin for Clearance of Methicillin-Resistant Staphylococcus aureus Colonization After Hospital Discharge: A Secondary Analysis of the Changing Lives by Eradicating Antibiotic Resistance Trial. |
|---|---|
| المؤلفون: | Miller LG; Infectious Disease Clinical Outcomes Research Unit, Division of Infectious Disease, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, USA., Singh R; Division of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Irvine, California, USA., Eells SJ; Infectious Disease Clinical Outcomes Research Unit, Division of Infectious Disease, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, USA., Gillen D; Division of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Irvine, California, USA., McKinnell JA; Infectious Disease Clinical Outcomes Research Unit, Division of Infectious Disease, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, USA., Park S; Division of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Irvine, California, USA., Tjoa T; Division of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Irvine, California, USA., Chang J; Division of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Irvine, California, USA., Rashid S; Division of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Irvine, California, USA., Macias-Gil R; Infectious Disease Clinical Outcomes Research Unit, Division of Infectious Disease, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, USA., Heim L; Division of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Irvine, California, USA., Gombosev A; Division of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Irvine, California, USA., Kim D; Division of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Irvine, California, USA., Cui E; Division of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Irvine, California, USA., Lequieu J; Division of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Irvine, California, USA., Cao C; Division of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Irvine, California, USA., Hong SS; Division of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Irvine, California, USA., Peterson EM; Division of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Irvine, California, USA., Evans KD; Division of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Irvine, California, USA., Launer B; Infectious Disease Clinical Outcomes Research Unit, Division of Infectious Disease, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, USA., Tam S; Division of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Irvine, California, USA., Bolaris M; Infectious Disease Clinical Outcomes Research Unit, Division of Infectious Disease, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, USA., Huang SS; Division of Infectious Diseases and Health Policy Research Institute, University of California, Irvine School of Medicine, Irvine, California, USA. |
| المصدر: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Feb 08; Vol. 76 (3), pp. e1208-e1216. |
| نوع المنشور: | Randomized Controlled Trial; Multicenter Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: Chicago, IL : The University of Chicago Press, c1992- |
| مواضيع طبية MeSH: | Methicillin-Resistant Staphylococcus aureus* , Staphylococcal Infections*/drug therapy , Staphylococcal Infections*/prevention & control, Adult ; Humans ; Mupirocin/therapeutic use ; Chlorhexidine/therapeutic use ; Anti-Bacterial Agents/therapeutic use ; Anti-Bacterial Agents/pharmacology ; Patient Discharge ; Aftercare ; Carrier State/drug therapy ; Carrier State/prevention & control ; Drug Resistance, Microbial ; Hospitals |
| مستخلص: | Background: The CLEAR Trial demonstrated that a multisite body decolonization regimen reduced post-discharge infection and hospitalization in methicillin-resistant Staphylococcus aureus (MRSA) carriers. Here, we describe decolonization efficacy. Methods: We performed a large, multicenter, randomized clinical trial of MRSA decolonization among adult patients after hospital discharge with MRSA infection or colonization. Participants were randomized 1:1 to either MRSA prevention education or education plus decolonization with topical chlorhexidine, oral chlorhexidine, and nasal mupirocin. Participants were swabbed in the nares, throat, axilla/groin, and wound (if applicable) at baseline and 1, 3, 6, and 9 months after randomization. The primary outcomes of this study are follow-up colonization differences between groups. Results: Among 2121 participants, 1058 were randomized to decolonization. By 1 month, MRSA colonization was lower in the decolonization group compared with the education-only group (odds ration [OR] = 0.44; 95% confidence interval [CI], .36-.54; P ≤ .001). A similar magnitude of reduction was seen in the nares (OR = 0.34; 95% CI, .27-.42; P < .001), throat (OR = 0.55; 95% CI, .42-.73; P < .001), and axilla/groin (OR = 0.57; 95% CI, .43-.75; P < .001). These differences persisted through month 9 except at the wound site, which had a relatively small sample size. Higher regimen adherence was associated with lower MRSA colonization (P ≤ .01). Conclusions: In a randomized, clinical trial, a repeated post-discharge decolonization regimen for MRSA carriers reduced MRSA colonization overall and at multiple body sites. Higher treatment adherence was associated with greater reductions in MRSA colonization. Competing Interests: Potential conflicts of interest. L. G. M. has served as a consultant or has received grants from Gilead Science, Achaogen, Merck, Abbott, Medline, and Cepheid and has received financial or material support from Medline, Sage, and Xttrium. R. S. has received financial or material support from Medline, Molnlycke, Sage, and Xttrium. L. H. has received financial or material support from Medline, Molnlycke, Sage, and Xttrium. J. A. M. has received research funding from Achaogen, Theravance Biopharma, Allergan, Cempra, Melinta Therapeutics, Menarini Group, Medline, and Thermo Fisher Scientific and has received financial or material support from Medline, Sage, and Xttrium. S. S. Huang has received financial or material support from Medline, Molnlycke, Sage, and Xttrium. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.) |
| References: | Clin Ther. 2001 Aug;23(8):1296-310. (PMID: 11558866) J Affect Disord. 1997 Mar;43(1):27-39. (PMID: 9127828) J Antimicrob Chemother. 2009 Jul;64(1):9-15. (PMID: 19451132) Clin Microbiol Infect. 2010 May;16(5):425-31. (PMID: 19689469) N Engl J Med. 2019 Feb 14;380(7):638-650. (PMID: 30763195) Am J Infect Control. 2009 Sep;37(7):603-5. (PMID: 19362391) J Hosp Infect. 2019 Nov;103(3):235-243. (PMID: 31494130) Infect Control Hosp Epidemiol. 2012 Feb;33(2):114-21. (PMID: 22227979) PLoS One. 2011;6(9):e24340. (PMID: 21949707) Int Dent J. 2002 Oct;52(5):337-45. (PMID: 12418602) Crit Care Med. 2009 Jun;37(6):1858-65. (PMID: 19384220) Infect Control Hosp Epidemiol. 2013 Jan;34(1):1-14. (PMID: 23221186) Clin Infect Dis. 2007 Aug 15;45(4):475-7. (PMID: 17638197) JAMA. 2006 Nov 22;296(20):2460-6. (PMID: 17119142) Ann Intern Med. 2001 May 15;134(10):968-77. (PMID: 11352698) Arch Intern Med. 1994 Jul 11;154(13):1505-8. (PMID: 8018006) N Engl J Med. 2010 Jan 7;362(1):9-17. (PMID: 20054045) JAMA Intern Med. 2013 Nov 25;173(21):1970-8. (PMID: 24043270) BMC Infect Dis. 2012 Nov 01;12:284. (PMID: 23116411) Emerg Infect Dis. 2007 Dec;13(12):1840-6. (PMID: 18258033) Antimicrob Agents Chemother. 2005 Apr;49(4):1465-7. (PMID: 15793127) N Engl J Med. 2013 Jun 13;368(24):2255-65. (PMID: 23718152) Antimicrob Resist Infect Control. 2016 Jun 14;5:25. (PMID: 27307987) Lancet. 2013 Mar 30;381(9872):1099-106. (PMID: 23363666) J Dent Hyg. 2001 Summer;75(3):233-9. (PMID: 11603305) Clin Infect Dis. 2008 Jul 15;47(2):176-81. (PMID: 18532892) Arch Intern Med. 2010 Jun 28;170(12):1045-9. (PMID: 20585070) Clin Infect Dis. 2012 Jun;54(11):1523-35. (PMID: 22474221) Clin Infect Dis. 2005 Jul 15;41(2):159-66. (PMID: 15983910) Infect Control Hosp Epidemiol. 2022 Sep;43(9):1276-1277. (PMID: 34027838) JAMA. 2015 Jun 2;313(21):2162-71. (PMID: 26034956) N Engl J Med. 2002 Jun 13;346(24):1871-7. (PMID: 12063371) N Engl J Med. 2005 Aug 4;353(5):487-97. (PMID: 16079372) Clin Infect Dis. 2019 Feb 1;68(4):545-553. (PMID: 30107401) Clin Infect Dis. 2002 Feb 15;34(4):425-33. (PMID: 11797167) |
| معلومات مُعتمدة: | KL2 TR000122 United States TR NCATS NIH HHS; R01 HS019388 United States HS AHRQ HHS |
| فهرسة مساهمة: | Keywords: MRSA; clinical trial; decolonization; post-discharge |
| المشرفين على المادة: | D0GX863OA5 (Mupirocin) R4KO0DY52L (Chlorhexidine) 0 (Anti-Bacterial Agents) |
| تواريخ الأحداث: | Date Created: 20220531 Date Completed: 20230210 Latest Revision: 20230602 |
| رمز التحديث: | 20230602 |
| مُعرف محوري في PubMed: | PMC10169430 |
| DOI: | 10.1093/cid/ciac402 |
| PMID: | 35640877 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!